Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-12-20
1998-03-17
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514332, 514551, 546255, 546335, 560 25, C07D40102, A61K 3144
Patent
active
057287180
ABSTRACT:
The present invention provides 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane (DAD) isosteres comprising benzamide, sulfonamide and anthranilamide subunits, a pharmaceutical composition comprising such compounds, a method of using such compounds to treat retroviral, specifically HIV and more specifically HIV-1 and HIV-2, infections in mammals, particularly humans, a method of synthesizing asymmetric DAD isosteres comprising benzamide, sulfonamide and anthranilamide subunits, and a method of using such compounds to assay new compounds for antiretroviral activity.
REFERENCES:
patent: 3838145 (1974-09-01), Alermatt
patent: 4051196 (1977-09-01), Wells et al.
patent: 4568666 (1986-02-01), McCullagh et al.
patent: 5142056 (1992-08-01), Kempe et al.
patent: 5180744 (1993-01-01), Hanson et al.
patent: 5214129 (1993-05-01), Luly et al.
patent: 5254724 (1993-10-01), Bergerson, Jr.
patent: 5256677 (1993-10-01), Sham et al.
patent: 5272175 (1993-12-01), Hansen, Jr. et al.
patent: 5354866 (1994-10-01), Kempf et al.
Chemical Abstracts, vol. 116, No. 21, Abstract 214,912m, May 25, 1992, p. 792.
Chemical Abstracts, vol. 115, No. 5, Abstract 50304r, Aug. 5, 1991, p. 714.
Bone et al., "X-ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseud C.sub.2 Symmetry," J. Am. Chem. Soc., 113:9382-9384 (Jul., 1994).
Erickson et al., "Design, Activity, and 2.8 .ANG. Crystal Structure of a C.sub.2 Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249:527-533 (Aug. 1990).
Flentge et al., "Symmetry-Based Inhibitors of HIV Protease With High Oral Bioavailability," Abstract, Amer. Chem. Society Mtg. (1994).
Green et al., "Symmetry-Based HIV Protease Inhibitors: Structure-Based Design of P2 Amino Acid Replacements," Abstract, Amer. Chem. Society Mtg. (1993).
Kempf et al., "Antiviral and Pharmacokinetic Properties of C.sub.2 Symmetric Inhibitors of the Human Immunodeficiency Virus Type 1 Protease," Antimicrobial Agents and Chemotherapy, 35(11):2209-2214 (Nov. 1991).
Kempf et al., "Design of Orally Bioavailable, Symmetry-Based Inhibitors of HIV Protease," Bioorganic & Medicinal Chemistry, 2(9):847-858 (1994).
Kempf et al., "Structure-Based, C.sub.2 Symmetric Inhibitors of HIV Protease," Journal of Medicinal Chemistry, 33(10):2687-2689 (1990).
Kempf et al, "Structure-Based Inhibitors of HIV Protease," Recent Advances in the Chem. of Anti-Infective Agents, Bently et al., eds. Royal Society of Chem., Cambridge (1993) pp. 297-313.
Kempf et al., "Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol," J. Med. Chem, 36:320-330 (1993).
Randad et al, "Symmetry-Based HIV Protease Inhibitors: Rational Design of Hydroxybenzamide as a Novel P.sub.2 Replacement," Abstract, AIDS Structure Mtg., NIH (1994).
Erickson John W.
Randad Ramnarayan S.
Davis Zinna Northington
The United States of America as represented by the Department of
LandOfFree
2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres compr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres compr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres compr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-958005